Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Morphic Holding, Inc. (MORF) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
09/26/2023 8-K Quarterly results
08/03/2023 8-K Quarterly results
Docs: "Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023 -Reported positive topline results from EMERALD-1study of MORF-057 in ulcerative colitis-"
05/03/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022 -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis&#59; topline data expected 2Q23-"
02/13/2023 8-K Quarterly results
01/20/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
11/02/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
08/03/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022 Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team"
06/21/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/24/2022 8-K Quarterly results
11/04/2021 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives&#59; phase 2 program in ulcerative colitis expected to begin 1Q22"
08/23/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors"
08/04/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives&#59; phase 2 program expected to begin 1Q22"
07/09/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "###"
06/21/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/05/2021 8-K Quarterly results
12/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors"
11/09/2020 8-K Quarterly results
Docs: "Press release issued by Morphic Holding, Inc. regarding its financial results for the quarter ended September 30, 2020"
09/23/2020 8-K Quarterly results
08/25/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
06/19/2020 8-K Submission of Matters to a Vote of Security Holders
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy